Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2018

Open Access 01-12-2018 | Research

Fear of disease progression in carriers of the m.3243A > G mutation

Authors: José A. E. Custers, Paul de Laat, Saskia Koene, Jan Smeitink, Mirian C. H. Janssen, Christianne Verhaak

Published in: Orphanet Journal of Rare Diseases | Issue 1/2018

Login to get access

Abstract

Background

Being diagnosed with mitochondrial disease due to the m.3243A > G mutation is frequently preceded by a long diagnostic process. The disease itself is characterized by heterogeneous course and expression, so leaving patients with considerable uncertainty regarding their prognosis and treatment possibilities. This could easily result in fear of disease progression. This study investigated the presence of this fear and its correlates with genetic characteristics and clinical disease severity in m.3243A > G carriers.

Methods

In total 125 eligible m.3243A > G mutation carriers were invited to participate in this cross-sectional study. After informed consent, participants completed questionnaires including items on socio-demographics, fear of progression, depression, anxiety, and quality of life. Clinical disease severity was assessed by the NMDAS questionnaire. Heteroplasmy levels were assessed in leucocytes, urine epithelial cells and buccal mucosa.

Results

Seventy-six carriers participated in this study. Results showed that 18% reported high fear of progression. Fear of progression was significantly related to all domains of quality of life. Furthermore, fear of progression was moderately correlated with feelings of depression (r = .37), and anxiety (r = .44). Patients with moderate or severe clinical symptoms on the NMDAS experienced more fear of progression than patients with mild clinical symptoms. Fear of progression was weakly correlated with heteroplasmy in leucocytes (r = .27) and buccal mucosa (r = .31).

Conclusions

A substantial part of m.3243A > G mutation carriers experience high levels of fear of progression which coincide with significantly lower quality of life. Only a small relation with disease characteristics was found. The impact of receiving a diagnosis without therapeutic possibilities on fear is important to consider.
Literature
1.
go back to reference Dankert A, Duran G, Engst-Hastreiter U, Keller M, Waadt S, Henrich G, et al. Progredienzangst bei Patienten mit Tumorerkrankungen, diabetes mellitus und entzündlich-rheumatischen Erkrankungen [fear of progression in patients with cancer, diabetes mellitus and chronic arthritis]. Rehabilitation. 2003;42:155–63.CrossRef Dankert A, Duran G, Engst-Hastreiter U, Keller M, Waadt S, Henrich G, et al. Progredienzangst bei Patienten mit Tumorerkrankungen, diabetes mellitus und entzündlich-rheumatischen Erkrankungen [fear of progression in patients with cancer, diabetes mellitus and chronic arthritis]. Rehabilitation. 2003;42:155–63.CrossRef
2.
go back to reference Haas RH, Parikh S, Falk MJ, Saneto RP, Wolf NI, Darin N, et al. Mitochondrial disease: a practical approach for primary care physicians. Pediatrics. 2007;120:1326–33.CrossRef Haas RH, Parikh S, Falk MJ, Saneto RP, Wolf NI, Darin N, et al. Mitochondrial disease: a practical approach for primary care physicians. Pediatrics. 2007;120:1326–33.CrossRef
3.
go back to reference Alston CL, Rocha MC, Lax NZ, Turnbull DM, Taylor RW. The genetics and pathology of mitochondrial disease. J Pathol. 2017;241:236–50.CrossRef Alston CL, Rocha MC, Lax NZ, Turnbull DM, Taylor RW. The genetics and pathology of mitochondrial disease. J Pathol. 2017;241:236–50.CrossRef
4.
go back to reference Smeitink J, van den Heuvel L, DiMauro S. The genetics and pathology of oxidative phosphorylation. Nature Rev. 2001;2:342–52.CrossRef Smeitink J, van den Heuvel L, DiMauro S. The genetics and pathology of oxidative phosphorylation. Nature Rev. 2001;2:342–52.CrossRef
5.
go back to reference Senger BA, Ward LD, Barbosa-Leiker C, Bindler RC. The parent experience of caring for a child with mitochondrial disease. J Pediatr Nurs. 2016;31:32–41.CrossRef Senger BA, Ward LD, Barbosa-Leiker C, Bindler RC. The parent experience of caring for a child with mitochondrial disease. J Pediatr Nurs. 2016;31:32–41.CrossRef
6.
go back to reference Rahman J, Rahman S. Mitochondrial medicine in the omics era. Lancet. 2018;391:2560–74.CrossRef Rahman J, Rahman S. Mitochondrial medicine in the omics era. Lancet. 2018;391:2560–74.CrossRef
7.
go back to reference Whittaker RG, Devine HE, Gorman GS, Schaefer AM, Horvath R, Ng Y, et al. Epilepsy in adults with mitochondrial disease: a cohort study. Ann Neurol. 2015;78:949–57.CrossRef Whittaker RG, Devine HE, Gorman GS, Schaefer AM, Horvath R, Ng Y, et al. Epilepsy in adults with mitochondrial disease: a cohort study. Ann Neurol. 2015;78:949–57.CrossRef
8.
go back to reference Herschbach P, Dinkel A. Fear of progression. In: Goerling U, editor. Recent results in Cancer research. Berlin: Springer; 2014. p. 11–29. Herschbach P, Dinkel A. Fear of progression. In: Goerling U, editor. Recent results in Cancer research. Berlin: Springer; 2014. p. 11–29.
9.
go back to reference Berg P, Book K, Dinkel A, Henrich G, Marten-Mittag B, Mertens D, et al. Progredienzangst bei chronischen Erkrankungen [fear of progression in chronic diseases]. Psychother Psychosom Med Psychol. 2011;61:32–7.CrossRef Berg P, Book K, Dinkel A, Henrich G, Marten-Mittag B, Mertens D, et al. Progredienzangst bei chronischen Erkrankungen [fear of progression in chronic diseases]. Psychother Psychosom Med Psychol. 2011;61:32–7.CrossRef
10.
go back to reference de Laat P, Koene S, van den Heuvel LWPJ, Rodenburg RJT, Janssen MCH, Smeitink JAM. Clinical features and heteroplasmy in blood, urine and saliva in 34 Dutch families carrying the m.3243A>G mutation. J Inherit Metab Dis. 2012;35:1059–69.CrossRef de Laat P, Koene S, van den Heuvel LWPJ, Rodenburg RJT, Janssen MCH, Smeitink JAM. Clinical features and heteroplasmy in blood, urine and saliva in 34 Dutch families carrying the m.3243A>G mutation. J Inherit Metab Dis. 2012;35:1059–69.CrossRef
11.
go back to reference Schaefer AM, Phoenix C, Elson JL, McFarland R, Chinnery PF, Turnbull DM. Mitochondrial disease in adults: a scale to monitor progression and treatment. Neurology. 2006;66:1932–4.CrossRef Schaefer AM, Phoenix C, Elson JL, McFarland R, Chinnery PF, Turnbull DM. Mitochondrial disease in adults: a scale to monitor progression and treatment. Neurology. 2006;66:1932–4.CrossRef
12.
go back to reference Herschbach P, Berg P, Dankert A, Duran G, Engst-Hastreiter U, Keller M, et al. Fear of progression in chronic diseases: psychometric properties of the fear of progression questionnaire. J Psychosom Res. 2005;58:505–11.CrossRef Herschbach P, Berg P, Dankert A, Duran G, Engst-Hastreiter U, Keller M, et al. Fear of progression in chronic diseases: psychometric properties of the fear of progression questionnaire. J Psychosom Res. 2005;58:505–11.CrossRef
13.
go back to reference Mehnert A, Herschbach P, Berg P, Henrich G, Koch U. Progredienzangst bei Brustkrebspatientinnen: validierung der Kurzform de Progredienzangstfragebogens. Z Psychom Med Psychother. 2006;52:274–88. Mehnert A, Herschbach P, Berg P, Henrich G, Koch U. Progredienzangst bei Brustkrebspatientinnen: validierung der Kurzform de Progredienzangstfragebogens. Z Psychom Med Psychother. 2006;52:274–88.
14.
go back to reference Kwakkenbos L, van den Hoogen FH, Custers J, Prins J, Vonk MC, van Lankveld WG, et al. Validity of the fear of progression questionnaire- short form in patients with systemic sclerosis. Arthritis Care Res. 2012;64:930–4.CrossRef Kwakkenbos L, van den Hoogen FH, Custers J, Prins J, Vonk MC, van Lankveld WG, et al. Validity of the fear of progression questionnaire- short form in patients with systemic sclerosis. Arthritis Care Res. 2012;64:930–4.CrossRef
15.
go back to reference Sarkar S, Scherwath A, Schirmer L, Schulz-Kindermann F, Neumann K, Kruse M, et al. Fear of recurrence and its impact on quality of life in patients with hematological cancers in the course of allogeneic hematopoietic SCT. Bone Marrow Transplant. 2014;49:1217–22.CrossRef Sarkar S, Scherwath A, Schirmer L, Schulz-Kindermann F, Neumann K, Kruse M, et al. Fear of recurrence and its impact on quality of life in patients with hematological cancers in the course of allogeneic hematopoietic SCT. Bone Marrow Transplant. 2014;49:1217–22.CrossRef
16.
go back to reference Sarkar S, Sautier L, Schilling G, Bokemeyer C, Koch U, Mehnert A. Anxiety and fear of recurrence and its association with supportive care needs and health-care service utilization in cancer patients. J Cancer Surviv. 2015;9:567–75.CrossRef Sarkar S, Sautier L, Schilling G, Bokemeyer C, Koch U, Mehnert A. Anxiety and fear of recurrence and its association with supportive care needs and health-care service utilization in cancer patients. J Cancer Surviv. 2015;9:567–75.CrossRef
17.
go back to reference van der Zee K, Sanderman R, Heyink JW, de Haes H. Psychometric qualities of the RAND 36-item health survey 1.0: a multidimensional measure of general health status. Int J Beh Med. 1996;3:104–22.CrossRef van der Zee K, Sanderman R, Heyink JW, de Haes H. Psychometric qualities of the RAND 36-item health survey 1.0: a multidimensional measure of general health status. Int J Beh Med. 1996;3:104–22.CrossRef
18.
go back to reference van der Zee KI, Sanderman R. Het meten van de algemene gezondheidstoestand met de Rand-36, een handleiding. Tweede herziene druk. UMCG/Rijksuniversiteit Groningen, Research Institute SHARE; 2012. van der Zee KI, Sanderman R. Het meten van de algemene gezondheidstoestand met de Rand-36, een handleiding. Tweede herziene druk. UMCG/Rijksuniversiteit Groningen, Research Institute SHARE; 2012.
19.
go back to reference Vodermaier A, Millman RD. Accuracy of the hospital anxiety and depression scale as screening tool in cancer patients: a systematic review and meta-analysis. Support Care Cancer. 2011;19:1899–908.CrossRef Vodermaier A, Millman RD. Accuracy of the hospital anxiety and depression scale as screening tool in cancer patients: a systematic review and meta-analysis. Support Care Cancer. 2011;19:1899–908.CrossRef
20.
go back to reference Spinhoven PH, Ormel J, Sloekers PPA, Kempen GIJM, Speckens AEM, van Hemert AM. A validation study of the hospital anxiety and depression scale (HADS) in different groups of Dutch subjects. Psychol Med. 1997;27:363–70.CrossRef Spinhoven PH, Ormel J, Sloekers PPA, Kempen GIJM, Speckens AEM, van Hemert AM. A validation study of the hospital anxiety and depression scale (HADS) in different groups of Dutch subjects. Psychol Med. 1997;27:363–70.CrossRef
21.
go back to reference Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. New York: Academic Press; 1988. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. New York: Academic Press; 1988.
22.
go back to reference Mehnert A, Berg P, Henrich G, Herschbach P. Fear of cancer progression and cancer-related intrusive cognitions in breast cancer survivors. Psychooncology. 2009;18:1273–80.CrossRef Mehnert A, Berg P, Henrich G, Herschbach P. Fear of cancer progression and cancer-related intrusive cognitions in breast cancer survivors. Psychooncology. 2009;18:1273–80.CrossRef
23.
go back to reference Leventhal H, Diefenbach M, Leventhal EA. Illness cognition: using common sense to understand treatment adherence and affect cognition interactions. Cog Ther Res. 1992;16:143–63.CrossRef Leventhal H, Diefenbach M, Leventhal EA. Illness cognition: using common sense to understand treatment adherence and affect cognition interactions. Cog Ther Res. 1992;16:143–63.CrossRef
24.
go back to reference National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology (NCCN guidelines): Distress management version 2.2013. National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology (NCCN guidelines): Distress management version 2.2013.
Metadata
Title
Fear of disease progression in carriers of the m.3243A > G mutation
Authors
José A. E. Custers
Paul de Laat
Saskia Koene
Jan Smeitink
Mirian C. H. Janssen
Christianne Verhaak
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2018
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-018-0951-y

Other articles of this Issue 1/2018

Orphanet Journal of Rare Diseases 1/2018 Go to the issue